[et_pb_section fb_built=”1″ _builder_version=”4.9.0″ _module_preset=”default”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.9.0″ _module_preset=”default”][et_pb_column type=”1_3″ _builder_version=”4.9.0″ _module_preset=”default”][et_pb_blurb title=”Newcastle disease virus (NDV)-based vaccines” _builder_version=”4.9.0″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
We use the Newcastle disease virus (NDV) expressing the antigen of interest as viral vector vaccines. We have developed NDV-based SARS-CoV-2 ancestral and variant vaccines (NDV-HXP-S) that could be given systemically (inactivated) or intranasally (live). The inactivated NDV-HXP-S ancestral vaccine is conditionally approved for EUA in Thailand.<\/p>\n
[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.9.0″ _module_preset=”default”][et_pb_blurb title=”Influenza virus vaccines” _builder_version=”4.9.0″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
We develop influenza virus vaccines with improved cross-protection. Our vaccine strategies focused on both the hemagglutinin (HA) and the neuraminidase (NA). Our “mosaic” HA-expressing influenza viruses vaccines aim to broaden antibody responses targeting the HA. We also designed and developed viruses with improved “visibility” and abundance of the NA.<\/p>\n
[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.9.0″ _module_preset=”default”][et_pb_blurb title=”Vaccine-induced immune responses in preclinical animal models” _builder_version=”4.9.0″ _module_preset=”default”]<\/p>\n
We are interested in investigating vaccine-induced humoral and cellular immune responses (B cell and T cell) in the preclinical animal models with a particular interests in mucosal immunity.<\/p>\n
[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
We use the Newcastle disease virus (NDV) expressing the antigen of interest as viral vector vaccines. We have developed NDV-based SARS-CoV-2 ancestral and variant vaccines (NDV-HXP-S) that could be given systemically (inactivated) or intranasally (live). The inactivated NDV-HXP-S ancestral vaccine is conditionally approved for EUA in Thailand.We develop influenza virus vaccines with improved cross-protection. Our […]<\/p>\n","protected":false},"author":592,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-57","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/pages\/57","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/users\/592"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/comments?post=57"}],"version-history":[{"count":10,"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/pages\/57\/revisions"}],"predecessor-version":[{"id":151,"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/pages\/57\/revisions\/151"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/weinasunlab\/wp-json\/wp\/v2\/media?parent=57"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}